RANDOMIZED TRIAL OF PROPHYLACTIC DAILY ASPIRIN IN BRITISH MALE DOCTORS
RANDOMIZED TRIAL OF PROPHYLACTIC DAILY ASPIRIN IN BRITISH MALE DOCTORS
复制标题
DOI：
10.1136/bmj.296.6618.313
复制
发表时间：
1988-01-30
影响因子：
105.7
通讯作者：
DOLL, R
中科院分区：
文献类型：
--
作者：
PETO, R;GRAY, R;DOLL, R
一项为期六年的随机试验对5139名健康的男性医生进行了研究，目的是观察每天服用500毫克阿司匹林是否会降低中风、心肌梗死或其他血管疾病的发病率和死亡率。虽然治疗组的总死亡率比对照组低10%，但这种差异在统计学上并不显著，而且主要涉及中风或心肌梗死以外的疾病。同样，两组在非致死性心肌梗死或卒中发生率方面也无显著差异。事实上，在服用阿司匹林的人群中，致残性中风更常见。然而，阿司匹林对非致死性中风或心肌梗死的影响的置信下限为25%。偏头痛和某些类型的肌肉骨骼疼痛在治疗组中的发生率明显低于对照组，但由于对照组未给予安慰剂，因此很难评估这些发现的相关性。治疗组白内障发生率无明显降低。在致残性卒中或血管性死亡中缺乏任何明显的减少，这与闭塞性血管疾病后抗血小板治疗的既定价值形成对比。
A six year randomised trial was conducted among 5139 apparently healthy male doctors to see whether 500 mg aspirin daily would reduce the incidence of and mortality from stroke, myocardial infarction, or other vascular conditions. Though total mortality was 10% lower in the treated than control group, this difference was not statistically significant and chiefly involved diseases other than stroke or myocardial infarction. Likewise, there was no significant difference in the incidence of non-fatal myocardial infarction or stroke.sbd.indeed, disabling strokes were somewhat commoner among those allocated aspirin. The lower confidence limit for the effect of aspirin on non-fatal stroke or myocardial infarction, however, was a substantial 25% reduction. Migraine and certain types of musculoskeletal pain were reported significantly less often in the treated than control group, but as the control group was not given a placebo the relevance of these findings was difficult to assess. There was no apparent reduction in the incidence of cataract in the treated group. The lack of any apparent reduction in disabling stroke or vascular death contrasts with the established value of antiplatelet treatment after occlusive vascular disease.